---
id: nccn-lymphoma-hodgkin-2024
title: "NCCN 2024 Clinical Practice Guidelines: Hodgkin Lymphoma"
short_title: "NCCN Hodgkin Lymphoma 2024"

organization: National Comprehensive Cancer Network
collaborators: null
country: US
url: https://www.nccn.org/guidelines/
doi: null
pmid: null
open_access: false

specialty: oncology
guideline_type: clinical-practice
evidence_system: NCCN
conditions:
  - Hodgkin lymphoma
  - lymphoma
  - classical Hodgkin lymphoma
tags:
  - ABVD
  - brentuximab vedotin
  - PET-CT
  - radiation therapy
  - checkpoint inhibitors

publication_date: 2024-08-01
previous_version_date: 2023-08-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-26
---

## Scope
2024 NCCN clinical practice guideline on the diagnosis, staging, and treatment of classical Hodgkin lymphoma (cHL).

## Key Recommendations

### Diagnosis
- Excisional or core biopsy; FNA insufficient.
- Histology: Reed-Sternberg cells, CD30+, CD15+.

### Staging
- Ann Arbor staging (I-IV) with B symptoms (fever, night sweats, weight loss).
- PET-CT (Deauville criteria).
- Bone marrow biopsy usually not needed if PET-CT done.

### Early-Stage (I-II) Favorable
- **ABVD x 2 cycles + ISRT (Involved-Site Radiation Therapy)** OR **ABVD x 4 cycles** (without RT).
- Interim PET after 2 cycles to assess response.

### Early-Stage (I-II) Unfavorable
- **ABVD x 4-6 cycles + ISRT** OR **BV-AVD x 4 cycles Â± RT** (BV = brentuximab vedotin).
- Escalated BEACOPP is an option for selected patients.

### Advanced-Stage (III-IV)
- **BV-AVD (Brentuximab Vedotin + AVD) x 6 cycles**: Preferred first-line; superior PFS vs. ABVD with growth factor support.
- **ABVD x 6 cycles**: Alternative.
- Interim PET to guide therapy; de-escalation possible if PET-negative.

### Relapsed/Refractory HL
- **Second-Line Chemotherapy + Autologous Stem Cell Transplant (ASCT)**: Standard approach for transplant-eligible patients.
- **Brentuximab Vedotin**: Post-ASCT consolidation or for non-transplant candidates.
- **PD-1 Inhibitors (Pembrolizumab, Nivolumab)**: For relapse after ASCT and BV.
- **Allogeneic Transplant**: For selected multiply-relapsed patients.

### Surveillance
- Regular clinical exams, labs, and imaging per NCCN recommendations; imaging may be reduced over time.
